This Article  • Full text  • PDF  • Correction  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citation map  • Citing articles on HighWire  • Citing articles on ISI (234)  • Contact me when this article is cited  Related Content  • Related letters  • Related article  • Similar articles in JAMA  Topic Collections  • Obesity  • Randomized Controlled Trial  • Treatment Adherence  • Adherence  • Alert me on articles by topic

RIO-North America: A Randomized Controlled Trial

F. Xavier Pi-Sunyer, MD; Louis J. Aronne, MD; Hassan M. Heshmati, MD; Jeanne Devin, MS; Julio Rosenstock, MD; for the RIO-North America Study Group

JAMA. 2006;295:761-775.

Context  Rimonabant, a selective cannabinoid-1 receptor blocker, may reduce body weight and improve cardiometabolic risk factors in patients who are overweight or obese.

Objective  To compare the efficacy and safety of rimonabant with placebo each in conjunction with diet and exercise for sustained changes in weight and cardiometabolic risk factors over 2 years.

Design, Setting, and Participants  Randomized, double-blind, placebo-controlled trial of 3045 obese (body mass index 30) or overweight (body mass index >27 and treated or untreated hypertension or dyslipidemia) adult patients at 64 US and 8 Canadian clinical research centers from August 2001 to April 2004.

Intervention  After a 4-week single-blind placebo plus diet (600 kcal/d deficit) run-in period, patients were randomized to receive placebo, 5 mg/d of rimonabant, or 20 mg/d of rimonabant for 1 year. Rimonabant-treated patients were rerandomized to receive placebo or continued to receive the same rimonabant dose while the placebo group continued to receive placebo during year 2.

Main Outcome Measures  Body weight change over year 1 and prevention of weight regain during year 2. Additional efficacy measures included changes in waist circumference, plasma lipid levels, and other cardiometabolic risk factors.

Results  At year 1, the completion rate was 309 (51%) patients in the placebo group, 620 (51%) patients in the 5 mg of rimonabant group, and 673 (55%) patients in the 20 mg of rimonabant group. Compared with the placebo group, the 20 mg of rimonabant group produced greater mean (SEM) reductions in weight (–6.3 [0.2] kg vs –1.6 [0.2] kg; P<.001), waist circumference (–6.1 [0.2] cm vs –2.5 [0.3] cm; P<.001), and level of triglycerides (percentage change, –5.3 [1.2] vs 7.9 [2.0]; P<.001) and a greater increase in level of high-density lipoprotein cholesterol (percentage change, 12.6 [0.5] vs 5.4 [0.7]; P<.001). Patients who were switched from the 20 mg of rimonabant group to the placebo group during year 2 experienced weight regain while those who continued to receive 20 mg of rimonabant maintained their weight loss and favorable changes in cardiometabolic risk factors. Use of different imputation methods to account for the high rate of dropouts in all 3 groups yielded similar results. Rimonabant was generally well tolerated; the most common drug-related adverse event was nausea (11.2% for the 20 mg of rimonabant group vs 5.8% for the placebo group).

Conclusions  In this multicenter trial, treatment with 20 mg/d of rimonabant plus diet for 2 years promoted modest but sustained reductions in weight and waist circumference and favorable changes in cardiometabolic risk factors. However, the trial was limited by a high drop-out rate and longer-term effects of the drug require further study.

Clinical Trials Registration  ClinicalTrials.gov Identifier: NCT00029861

Author Affiliations: Obesity Research Center, St Luke’s-Roosevelt Hospital Center, Columbia University College of Physicians and Surgeons, New York, NY (Dr Pi-Sunyer); Department of Medicine, Cornell Weil Medical College, New York, NY (Dr Aronne); Sanofi-Aventis, Malvern, Pa (Dr Heshmati and Ms Devin); and Dallas Diabetes and Endocrine Center, Dallas, Tex (Dr Rosenstock).

RELATED LETTERS

Effect of Rimonabant on Weight and Cardiometabolic Risk Factors
Kishore M. Gadde
JAMA. 2006;296(6):649-650.
EXTRACT | FULL TEXT  

Effect of Rimonabant on Weight and Cardiometabolic Risk Factors—Reply
F. Xavier Pi-Sunyer
JAMA. 2006;296(6):650-651.
EXTRACT | FULL TEXT  

RELATED ARTICLE

Obesity Research—Limitations of Methods, Measurements, and Medications
Denise G. Simons-Morton, Eva Obarzanek, and Jeffrey A. Cutler
JAMA. 2006;295(7):826-828.
EXTRACT | FULL TEXT  

THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

Long-term effect of CB1 blockade with rimonabant on cardiometabolic risk factors: two year results from the RIO-Europe Study
Van Gaal et al.
Eur Heart J 2008;0:ehn076v1-11.
ABSTRACT | FULL TEXT  

Effect of Rimonabant on Progression of Atherosclerosis in Patients With Abdominal Obesity and Coronary Artery Disease: The STRADIVARIUS Randomized Controlled Trial
Nissen et al.
JAMA 2008;299:1547-1560.
ABSTRACT | FULL TEXT  

The Hope and Fear of Rimonabant
Rumsfeld and Nallamothu
JAMA 2008;299:1601-1602.
FULL TEXT  

The Obesity Epidemic: Pharmacological Challenges
Bloom et al.
Mol. Interv. 2008;8:82-98.
ABSTRACT | FULL TEXT  

Long-term Effects of Weight-Reducing Interventions in Hypertensive Patients: Systematic Review and Meta-analysis
Horvath et al.
Arch Intern Med 2008;168:571-580.
ABSTRACT | FULL TEXT  

HDL-cholesterol modulation and its impact on the management of cardiovascular risk
Ferns and Keti
Ann Clin Biochem 2008;45:122-128.
ABSTRACT | FULL TEXT  

Whole-Body Biodistribution and Radiation Dosimetry of the Human Cannabinoid Type-1 Receptor Ligand 18F-MK-9470 in Healthy Subjects
Van Laere et al.
JNM 2008;49:439-445.
ABSTRACT | FULL TEXT  

Consensus on infertility treatment related to polycystic ovary syndrome
The Thessaloniki ESHRE/ASRM-Sponsored PCOS Consens
Hum Reprod 2008;23:462-477.
ABSTRACT | FULL TEXT  

From individual risk factors and the metabolic syndrome to global cardiometabolic risk
Despres et al.
Eur Heart J Suppl 2008;10:B24-B33.
ABSTRACT | FULL TEXT  

Endocannabinoid system and its implications for obesity and cardiometabolic risk
Nesto and Mackie
Eur Heart J Suppl 2008;10:B34-B41.
ABSTRACT | FULL TEXT  

Needs Assessment
The Diabetes Educator 2008;34:30S-31S.
FULL TEXT  

Management Through Risk Factor Modification
Boyd
The Diabetes Educator 2008;34:42S-48S.
ABSTRACT | FULL TEXT  

Surgical treatment of obesity
Bult et al.
Eur J Endocrinol 2008;158:135-145.
ABSTRACT | FULL TEXT  

Addressing Overweight and Obesity: Evolving to a Medical Consensus
JAOA: Journal of the American Osteopathic Association 2008;108:S2-S15.
ABSTRACT | FULL TEXT  

Primary Prevention of Cardiovascular Disease in People With Dysglycemia
Bianchi et al.
Diabetes Care 2008;31:S208-S214.
ABSTRACT | FULL TEXT  

Efficacy and Safety of Rimonabant for Improvement of Multiple Cardiometabolic Risk Factors in Overweight/Obese Patients: Pooled 1-year data from the Rimonabant in Obesity (RIO) program
Van Gaal et al.
Diabetes Care 2008;31:S229-S240.
ABSTRACT | FULL TEXT  

Is Weight Loss Beneficial for Reduction of Morbidity and Mortality?: What is the controversy about?
Nilsson
Diabetes Care 2008;31:S278-S283.
ABSTRACT | FULL TEXT  

Are there specific treatments for the metabolic syndrome?
Giugliano et al.
Am. J. Clin. Nutr. 2008;87:8-11.
ABSTRACT | FULL TEXT  

Schizophrenia Host Vulnerability and Risk of Metabolic Disturbances During Treatment with Antipsychotics
Buckley et al.
Focus 2008;6:172-179.
ABSTRACT | FULL TEXT  

A neutral CB1 receptor antagonist reduces weight gain in rat
Chambers et al.
Am. J. Physiol. Regul. Integr. Comp. Physiol. 2007;293:R2185-R2193.
ABSTRACT | FULL TEXT  

Review: The metabolic syndrome as an endocrine disease: is there an effective pharmacotherapeutic strategy optimally targeting the pathogenesis?
Schindler
Therapeutic Advances in Cardiovascular Disease 2007;1:7-26.
ABSTRACT  

State of the Art Review: Long-term Pharmacotherapy for Overweight and Obesity: A Review of Sibutramine, Orlistat, and Rimonabant
Dunican et al.
AMERICAN JOURNAL OF LIFESTYLE MEDICINE 2007;1:367-388.
ABSTRACT  

What's Ahead for Rimonabant?
Law
DOC News 2007;4:10-10.
FULL TEXT  

CB1 receptor antagonist AVE1625 affects primarily metabolic parameters independently of reduced food intake in Wistar rats
Herling et al.
Am. J. Physiol. Endocrinol. Metab. 2007;293:E826-E832.
ABSTRACT | FULL TEXT  

Pharmacotherapeutic Options for Overweight Adolescents
Dunican et al.
The Annals of Pharmacotherapy 2007;41:1445-1455.
ABSTRACT | FULL TEXT  

High-Density Lipoprotein as a Therapeutic Target: A Systematic Review
Singh et al.
JAMA 2007;298:786-798.
ABSTRACT | FULL TEXT  

Emerging pharmacotherapies for smoking cessation
Garwood and Potts
Am J Health Syst Pharm 2007;64:1693-1698.
ABSTRACT | FULL TEXT  

Pharmacological Inhibition of CB1 Cannabinoid Receptor Protects Against Doxorubicin-Induced Cardiotoxicity
Mukhopadhyay et al.
J Am Coll Cardiol 2007;50:528-536.
ABSTRACT | FULL TEXT  

Guidelines for the diagnosis and treatment of non-ST-segment elevation acute coronary syndromes: The Task Force for the Diagnosis and Treatment of Non-ST-Segment Elevation Acute Coronary Syndromes of the European Society of Cardiology
Authors/Task Force Members et al.
Eur Heart J 2007;28:1598-1660.
FULL TEXT  

2007 Guidelines for the Management of Arterial Hypertension: The Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC)
Authors/Task Force Members: et al.
Eur Heart J 2007;0:ehm236v1-75.
FULL TEXT  

Less weight or more hype with {blacktriangledown}rimonabant?
DTB 2007;45:41-44.
ABSTRACT | FULL TEXT  

Pharmacological Treatment of the Overweight Patient
Bray and Greenway
Pharmacol. Rev. 2007;59:151-184.
FULL TEXT  

Genetic Variations at the Endocannabinoid Type 1 Receptor Gene (CNR1) Are Associated with Obesity Phenotypes in Men
Russo et al.
J. Clin. Endocrinol. Metab. 2007;92:2382-2386.
ABSTRACT | FULL TEXT  

Rimonabant: Just an Antiobesity Drug? Current Evidence on Its Pleiotropic Effects
Bifulco et al.
Mol. Pharmacol. 2007;71:1445-1456.
ABSTRACT | FULL TEXT  

Adipose Tissue and Atherosclerosis: Exploring the Connection
Fantuzzi and Mazzone
Arterioscler. Thromb. Vasc. Bio. 2007;27:996-1003.
ABSTRACT | FULL TEXT  

The Role of Endocannabinoid System Blockade in the Treatment of the Metabolic Syndrome
Kakafika et al.
J Clin Pharmacol 2007;47:642-652.
ABSTRACT | FULL TEXT  

The Year in Atherothrombosis
Sanz et al.
J Am Coll Cardiol 2007;49:1740-1749.
FULL TEXT  

Hypertriglyceridemia: its etiology, effects and treatment
Yuan et al.
CMAJ 2007;176:1113-1120.
ABSTRACT | FULL TEXT  

Requirement of Cannabinoid Receptor Type 1 for the Basal Modulation of Hypothalamic-Pituitary-Adrenal Axis Function
Cota et al.
Endocrinology 2007;148:1574-1581.
ABSTRACT | FULL TEXT  

Rimonabant: A novel selective cannabinoid-1 receptor antagonist for treatment of obesity
Patel and Pathak
Am J Health Syst Pharm 2007;64:481-489.
ABSTRACT | FULL TEXT  

Why do obese patients not lose more weight when treated with low-calorie diets? A mechanistic perspective
Heymsfield et al.
Am. J. Clin. Nutr. 2007;85:346-354.
ABSTRACT | FULL TEXT  

Pharmacologic Treatment Options for Obesity: Current and Potential Medications
Fujioka and Lee
Nutr Clin Pract 2007;22:50-54.
ABSTRACT | FULL TEXT  

Pharmacotherapy of Childhood Obesity: An evidence-based, conceptual approach
Freemark
Diabetes Care 2007;30:395-402.
FULL TEXT  

Prevention of Plasticity of Endocannabinoid Signaling Inhibits Persistent Limbic Hyperexcitability Caused by Developmental Seizures
Chen et al.
J. Neurosci. 2007;27:46-58.
ABSTRACT | FULL TEXT  

Emerging Therapeutic Strategies for Obesity
Foster-Schubert and Cummings
Endocr. Rev. 2006;27:779-793.
ABSTRACT | FULL TEXT  

Weight Control in Individuals With Diabetes
Bloomgarden
Diabetes Care 2006;29:2749-2754.
FULL TEXT  

Effects of Rimonabant (SR141716) on Fasting-Induced Hypothalamic-Pituitary-Adrenal Axis and Neuronal Activation in Lean and Obese Zucker Rats
Doyon et al.
Diabetes 2006;55:3403-3410.
ABSTRACT | FULL TEXT  

The Year in Epidemiology, Health Services Research, and Outcomes Research
Krumholz and Masoudi
J Am Coll Cardiol 2006;48:1886-1895.
FULL TEXT  

The Endocannabinoid System as a Target for the Treatment of Visceral Obesity and Metabolic Syndrome
KYROU et al.
Ann. N. Y. Acad. Sci. 2006;1083:270-305.
ABSTRACT | FULL TEXT  

Dysregulation of the Peripheral and Adipose Tissue Endocannabinoid System in Human Abdominal Obesity
Bluher et al.
Diabetes 2006;55:3053-3060.
ABSTRACT | FULL TEXT  

ABC of obesity. Management: part II--drugs.
Lean and Finer
BMJ 2006;333:794-797.
FULL TEXT  

The Endocannabinoid System as an Emerging Target of Pharmacotherapy
Pacher et al.
Pharmacol. Rev. 2006;58:389-462.
ABSTRACT | FULL TEXT  

Cannabinoid-1 Receptor Antagonist, Rimonabant, for Management of Obesity and Related Risks
Gadde and Allison
Circulation 2006;114:974-984.
FULL TEXT  

Effect of rimonabant on weight and cardiometabolic risk factors.
Gadde
JAMA 2006;296:649-650.
FULL TEXT  

Clinical Use of the Metabolic Syndrome: Why the Confusion?
Blaha and Elasy
Clin. Diabetes 2006;24:125-131.
ABSTRACT | FULL TEXT  

Cannabinoids Biology: The Search for New Therapeutic Targets
Felder et al.
Mol. Interv. 2006;6:149-161.
ABSTRACT | FULL TEXT  

From the Library
Br. J. Ophthalmol. 2006;90:804-804.
FULL TEXT  

Rimonabant Reduces Cardiometabolic Risks and Weight
DOC News 2006;3:12-12.
FULL TEXT  

Simple Pill Not a Simple Answer to Obesity
Journal Watch Cardiology 2006;2006:1-1.
FULL TEXT  

What's new in the other general journals.
Fister
BMJ 2006;332:477-478.
FULL TEXT  

Obesity Research--Limitations of Methods, Measurements, and Medications
Simons-Morton et al.
JAMA 2006;295:826-828.
FULL TEXT